Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Ocugen Inc (OCGN)

Ocugen Inc (OCGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes GlobeNewswire - Thu May 14, 3:30PM CDT

MALVERN, Pa., May 14, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the closing...

OCGN : 1.3900 (-4.79%)
Ocugen to Participate in Upcoming May Scientific and Investor Conferences GlobeNewswire - Wed May 13, 6:02AM CDT

MALVERN, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the...

OCGN : 1.3900 (-4.79%)
Ocugen: Q1 Earnings Snapshot AP - Tue May 5, 7:40AM CDT

Ocugen: Q1 Earnings Snapshot

OCGN : 1.3900 (-4.79%)
Ocugen Provides Business Update with First Quarter 2026 Financial Results GlobeNewswire - Tue May 5, 7:32AM CDT

Conference Call and Webcast Today at 8:30 a.m. ET Positive 12-month data from the OCU410 Phase 2 ArMaDa clinical trial for geographic atrophy (GA) indicates a statistically significant (p

OCGN : 1.3900 (-4.79%)
Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes GlobeNewswire - Tue May 5, 7:12AM CDT

MALVERN, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen”) (NASDAQ: OCGN) today announced the pricing of $115 million aggregate principal amount of 6.75% Convertible Senior Notes due...

OCGN : 1.3900 (-4.79%)
Ocugen's Gene Therapy Timeline Finally Gets a Number Tomorrow Barchart - Mon May 4, 4:22PM CDT

Barchart Research What to Expect from OCGN Earnings OCGN Generated May 4, 2026 Current Price $1.8500 EPS Estimate $$-0.05 Consensus Rating Strong Buy Average Move 6.53% Ocugen's Gene Therapy Timeline Finally...

OCGN : 1.3900 (-4.79%)
Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes GlobeNewswire - Mon May 4, 3:01PM CDT

MALVERN, Pa., May 04, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced...

OCGN : 1.3900 (-4.79%)
Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results GlobeNewswire - Wed Apr 29, 6:02AM CDT

MALVERN, Pa., April 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that...

OCGN : 1.3900 (-4.79%)
Ocugen to Present at April 2026 Investor and Industry Conferences GlobeNewswire - Thu Apr 23, 6:02AM CDT

MALVERN, Pa., April 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that...

OCGN : 1.3900 (-4.79%)
Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease GlobeNewswire - Wed Apr 1, 6:02AM CDT

GARDian3 trial enrollment and dosing completed (N=63) in less than nine months Topline results expected in 2Q27 with BLA to follow by mid-2027 OCU410ST represents a potential first-in-class, one-time...

OCGN : 1.3900 (-4.79%)

Barchart Exclusives

Lockheed Martin Stock Looks Well-Positioned to Get a Big Lift From the Very Costly Golden Dome Initiative Barchart - 11 minutes ago
LMT stock shows multiple, positive catalysts, with the Golden Dome being among the largest. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.